Press Releases

Telix today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara®1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed. Amino acid PET is included in U.S. and European clinical practice guidelines for the imaging of gliomas2, however there is no FDA-approved targeted am

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics. Tantti’s DuloCore&r

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United States. ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch, and was developed to provide long-term dise

Regeneration Biomedical, Inc., a clinical-stage company developing autologous stem cell treatments for neurodegenerative diseases, today announced a presentation on early data on the first two subjects from a Phase 1 clinical trial of Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs) administered directly into lateral ventricles of the brain in patients with Alzheimer’s Disease (AD). The data will be presented at the Alzheimer’s Association International C

ProMIS Neurosciences, Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced positive top-line data from the first four cohorts of its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers. The Phase 1a clinical data, which has been col

 Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it has commenced a Phase 1 first-in-human clinical trial (CITADEL-123) of 123I-ATT001, its Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma. The trial opened at University College London Hospitals (UCLH) and will assess the safety and early efficacy of Ariceum's radiotherape

BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States. BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of t

HYD LLC for Cancer Research and Drug Development (HYD or the Company) today announces two independent review papers in Nutrients -  Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials and Frontiers in Pharmacology – The Biological Impact of Deuterium and Therapeutic Potential of Deuterium-depleted Water. These review papers culminate 30 years of research into Deuterium Depleted Water (DDW) and set out the role of Deuterium-Depleted Wa

OS Therapies, Inc., a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced positive data from a Phase 1 clinical trial of OST-HER2 in patients with HER2-expressing solid tumors in breast cancer and other cancers. Additionally, the Company announced positive preclinical efficacy data for OST-HER2 in multiple models of breast cancer. The FDA has granted Rare Pediatric Disease Designat

OSE Immunotherapeutics SA, today announced positive topline results from its Phase 2 CoTikiS randomized, double-blind, placebo-controlled proof-of-concept study with Lusvertikimab, a pure IL-7 receptor antagonist, demonstrating significant efficacy results as measured by improvement in Modified Mayo Score** (at Week 10, the primary endpoint of the induction phase of treatment). A favorable safety profile was observed during both the induction phase and the 6-month open-label extension phase o